Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 786 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade... June 22, 2022 The Taylor Family Foundation gives £2.1m to support head and neck... December 12, 2022 Bariatric Surgery May Reduce the Risk of Some Common Cancers December 2, 2022 Should People With Cancer Be Tested for Hepatitis B? July 27, 2020 Load more HOT NEWS Charity promotes eco-fashion with collection at Love Not Landfill pop-up ¿Pueden confundirse los síntomas del cáncer con la menopausia? Study Says Gold Particles Injected into Tumors May Improve Cancer Patients’... ESMO Publishes First Guidance on the Safe Use of Large Language...
